Borderline Personality Disorder
4
Pipeline Programs
4
Companies
4
Clinical Trials
2 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
3
0
0
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Small Molecule
2100%
+ 3 programs with unclassified modality
Competitive Landscape
4 companies ranked by most advanced pipeline stage
Boehringer IngelheimINGELHEIM, Germany
2 programs1
1
BI 1358894Phase 21 trial
BI 3031185Phase 11 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
2028
Genomicsvafidemstat
Boehringer IngelheimBI 1358894
Boehringer IngelheimBI 3031185
Heidelberg PharmaMentalization-Based Treatment
Clinical Trials (4)
Total enrollment: 1,000 patients across 4 trials
Study to Test the Efficacy and Safety of Vafidemstat in Adult Borderline Personality Disorder Population
Start: Mar 2021Est. completion: Nov 2023210 patients
Phase 2Completed
A Study to Test Different Doses of BI 1358894 and Find Out Whether They Reduce Symptoms in People With Borderline Personality Disorder
Start: Nov 2020Est. completion: Jan 2023390 patients
Phase 2Completed
A Study to Test How BI 3031185 is Tolerated by People With Borderline Personality Disorder or Attention-deficit/Hyperactivity Disorder
Start: Aug 2025Est. completion: Nov 202696 patients
Phase 1Recruiting
Mentalization-based Treatment Versus Bona-fide Treatment for Patients With Borderline Personality Disorder in Germany
Start: Feb 2024Est. completion: Mar 2028304 patients
N/ARecruiting
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 actively recruiting trials targeting 1,000 patients
4 companies competing in this space